ARFGEF1

Across TCGA pan-cancer cohorts, ARFGEF1 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of ARFGEF1’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where ARFGEF1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARFGEF1 is over-expressed in tumor, although a few such as KIRC and KIRP show the opposite, repressed pattern.

LIHC, HNSC, and BLCA are the cancer types where ARFGEF1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARFGEF1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+1.103	<.001	9	view →
HNSC	All	All	+0.460	.001	8	view →
BLCA	All	III,IV	+0.730	<.001	7	view →
LUAD	Male	All	+0.669	<.001	7	view →
LUSC	All	All	+0.441	<.001	7	view →
BRCA	All	III,IV	+0.929	<.001	6	view →
STAD	All	II,III,IV	+0.778	.001	6	view →
KIRC	Male	II,III,IV	−0.565	<.001	6	view →
CHOL	All	All	+1.730	<.001	5	view →
KICH	All	IV	+0.969	.007	2	view →
KIRP	Male	All	−0.411	.008	2	view →
ESCA	Female	All	+0.549	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

ARFGEF1–LIHC

Open the LIHC breakdown →